Solvonis Therapeutics (LSE:SVNS) Operating Margin %: 0.00% (As of Dec. 2025)


What is Solvonis Therapeutics Operating Margin %?

Solvonis Therapeutics LSE:SVNS -7.69% Operating Margin % is 0.00% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 3,038 Industrial Products companies, Solvonis Therapeutics ranks worse than 32916.36% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Solvonis Therapeutics's Operating Income for the six months ended in Dec. 2025 was £-1.96 Mil. Solvonis Therapeutics's Revenue for the six months ended in Dec. 2025 was £0.00 Mil. Therefore, Solvonis Therapeutics's Operating Margin % for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Solvonis Therapeutics's Operating Margin % or its related term are showing as below:


LSE:SVNS's Operating Margin % is not ranked *
in the Industrial Products industry.
Industry Median: 6.53
* Ranked among companies with meaningful Operating Margin % only.

Solvonis Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Solvonis Therapeutics's Operating Income for the six months ended in Dec. 2025 was £-1.96 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was £-3.58 Mil.

Warning Sign:

Solvonis Therapeutics PLC has never been profitable in the past 3 years. It lost money every year.


Solvonis Therapeutics  (LSE:SVNS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Solvonis Therapeutics Operating Margin % Related Terms


Solvonis Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Solvonis Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solvonis Therapeutics Operating Margin % Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -85.00 -496.49 -376.49 0.00 0.00

Solvonis Therapeutics Semi-Annual Data
May18 May19 May20 May21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -340.35 0.00 0.00 0.00 0.00

LSE:SVNS vs GEV, ETN, PH: Operating Margin % Comparison

For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solvonis Therapeutics Operating Margin % vs Industrial Products Industry

For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's Operating Margin % falls into.



Solvonis Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Solvonis Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-3.575 / 0
= %

Solvonis Therapeutics's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-1.958 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Solvonis Therapeutics (LSE:SVNS) has a Operating Margin % of 0.00% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Solvonis Therapeutics and its competitors. According to the industry distribution chart, Solvonis Therapeutics ranks #999999 out of 3038 companies in the Industrial Products industry.
Is Solvonis Therapeutics' Operating Margin % too high?
Solvonis Therapeutics' current Operating Margin % is 0.00%. Based on the distribution chart, Solvonis Therapeutics ranks #999999 out of 3038 companies in the Industrial Products industry, which is in the bottom quartile relative to peers.
How does Solvonis Therapeutics' Operating Margin % compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Solvonis Therapeutics ranks #999999 out of 3038 companies for Operating Margin %. This places Solvonis Therapeutics in the lower half of its industry. The industry median Operating Margin % is 6.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for an Industrial Products company?
The median Operating Margin % among Industrial Products companies is 6.53, based on 3,038 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Solvonis Therapeutics and its competitors. For the Industrial Products industry, the median Operating Margin % is 6.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solvonis Therapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Solvonis Therapeutics (LSE:SVNS) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.00 — trading 91% below its estimated fair value. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Solvonis Therapeutics (LSE:SVNS), the current Operating Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solvonis Therapeutics Business Description

Other Exchanges J4I:Germany
Address Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.